Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Medtronic
McKinsey
AstraZeneca
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AUY922

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AUY922: Sponsors, patents, clinical trial progress

AUY922 is an investigational drug.

There have been 25 clinical trials for AUY922. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2012.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and SCRI Development Innovations, LLC.

There are thirty-five US patents protecting this investigational drug and three hundred and ninety-one international patents.

Recent Clinical Trials for AUY922
TitleSponsorPhase
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerNovartis PharmaceuticalsPhase 2
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerJonsson Comprehensive Cancer CenterPhase 1

See all AUY922 clinical trials

Clinical Trial Summary for AUY922

Top disease conditions for AUY922
Top clinical trial sponsors for AUY922

See all AUY922 clinical trials

US Patents for AUY922

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AUY922   Start Trial Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta Berg LLC (Nashville, TN)   Start Trial
AUY922   Start Trial Resorcinol derivative as HSP90 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN)   Start Trial
AUY922   Start Trial Compounds targeting proteins, compositions, methods, and uses thereof Biotheryx, Inc. (Chappaqua, NY)   Start Trial
AUY922   Start Trial Chimeric compounds targeting proteins, compositions, methods, and uses thereof BioTheryX, Inc. (Chappaqua, NY)   Start Trial
AUY922   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
AUY922   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
AUY922   Start Trial Nanoparticle delivery systems CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AUY922

Drugname Country Document Number Estimated Expiration Related US Patent
AUY922 Australia 2015269054 2034-06-06   Start Trial
AUY922 Canada 2951265 2034-06-06   Start Trial
AUY922 European Patent Office 3152307 2034-06-06   Start Trial
AUY922 World Intellectual Property Organization (WIPO) 2015188198 2034-06-06   Start Trial
AUY922 Australia 2016208863 2035-01-22   Start Trial
AUY922 Canada 2974756 2035-01-22   Start Trial
AUY922 China 107108591 2035-01-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Merck
McKesson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.